Introduction
============

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. COPD is a major cause of chronic morbidity and mortality worldwide.[@b1-copd-13-3503] Inhaled corticosteroids (ICSs) are important drugs for treating bronchial asthma. Additionally, ICSs are used to treat patients with severe COPD who suffer from repeated exacerbations. Compared with systemic use of corticosteroids, serious adverse events with ICS are rare, but local adverse events, such as oral candidiasis and hoarseness, have been reported.[@b2-copd-13-3503] In recent reports, the forced expiratory volume in 1 second markedly decreased when ICS administration was interrupted.[@b3-copd-13-3503],[@b4-copd-13-3503] Recently, dual therapy was shown to be inferior to triple therapy for acute exacerbation of COPD.[@b5-copd-13-3503] ICSs are also important drugs for treating COPD.

ICSs were recently reported to be associated with a high frequency of pneumonia. In the Toward a Revolution in COPD Health (TORCH) study, the ICS group had a significantly higher frequency of pneumonia than did the placebo group in 2007.[@b6-copd-13-3503] Although similar results have been reported since 2007,[@b7-copd-13-3503] the effect of ICS on mortality of pneumonia is unclear. Other studies have reported that the risk of pneumonia is not related to ICS use.[@b8-copd-13-3503],[@b9-copd-13-3503] Moreover, another study showed that use of ICS was not associated with an increased risk of pneumonia in patients with asthma.[@b10-copd-13-3503] Fluticasone/salmeterol (FP/SM) use tends to show a higher risk of pneumonia than does budesonide/formoterol (BUD/FM) use.[@b11-copd-13-3503] Therefore, controversy remains concerning the relationship between ICS and pneumonia. These previous findings were based on studies of Caucasians. Racial differences in the risk of contracting pulmonary diseases, such as drug-induced pneumonia with gefitinib administration, have been well documented.[@b12-copd-13-3503] However, few reports have been published concerning the relationship between ICS and the risk of pneumonia in Japan. Moreover, there is little information on the types of ICS. To clarify the relationship between ICS use and pneumonia in Japanese patients with COPD, we retrospectively analyzed the incidence of pneumonia in patients with COPD at our hospital.

Patients and methods
====================

Patients
--------

Patients with COPD were retrospectively investigated at our hospital using medical records. We investigated the medical records from January 2009 to August 2013. The morbidity and mortality rates, ICS use, age, sex, and COPD classification were all evaluated, as was long-term safety. The incidence of pneumonia was monitored for 3 years, as described in the TORCH study.[@b6-copd-13-3503] All patients with pneumonia due to infectious organisms were enrolled. Chest X-rays and chest computed tomography were performed to confirm pneumonia. A group of patients with COPD who received ICS and a group of patients with COPD who did not receive ICS were compared each other.

Risk factors for pneumonia
--------------------------

The risk factors for pneumonia, besides ICS use, were investigated. We classified ICS-treated patients with COPD into two groups: pneumonia and nonpneumonia groups. These two groups were matched to controls by age, sex, and ICS type for a case--control study. The ratio of patients in the pneumonia and nonpneumonia groups was 1:2. We compared the smoking history, oral steroid administration, oxygen therapy, inoculation with a pneumococcus vaccine, serum albumin levels, and body mass index (BMI) between the two groups.

Ethics of clinical practice
---------------------------

This study was approved by the local institutional review board of Fukuoka University Hospital (approval number: 15-8-03, approved on September 29, 2015) and was conducted in compliance with the guidelines of good clinical practice and the principles of the Declaration of Helsinki. The patient consent to review their medical records was not required by the local institutional review board of Fukuoka University Hospital since correct number for events are very important and exclusion of any patients limited the scientific validity of the analyses. Moreover, the study poses no clinical risk or harm to the subjects included in the study and any additional risks are limited to those of privacy and confidentiality which are minimal.

Statistical analysis
--------------------

Statistical analysis was performed using the chi-squared test or nonparametric analysis (Mann--Whitney *U* test). A *P*-value \<0.05 was considered statistically significant. Univariate analyses were performed to select a first set of covariates to be tested for inclusion in a multivariate model, in which all covariates with a *P*-value \<0.2 by simple logistic regression analysis were included. After completion of univariate analyses, a multiple logistic regression model was selected by the stepwise method. These statistical analyses were performed using the Stata version 9.2 software (StataCorp LLC, College Station, TX, USA).

Results
=======

A total of 252 patients with COPD had a record of ICS treatment during the study period. The median age was 75 years (range: 47--94 years), and 84% were men. Sixty (24%) patients had been treated for more than 3 years. The types of ICS were as follows: FP/SM was used in 193 patients; BUD/FM in 30; FP in 12; BUD in 2; and others in 15 ([Table 1](#t1-copd-13-3503){ref-type="table"}). All of the patients with COPD were smokers.

Fifty-one patients developed pneumonia among the 639 (7.98%) patients with COPD. Among 252 ICS-treated patients with COPD, 13 developed pneumonia. The incidence of pneumonia among the treated patients was 5.16%. The median age was 80 years (69--94 years), and 92% were men. Six patients had malignant tumors, two had diabetes, and two had heart failure. Classification of COPD was defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) A--D grades, with grade A in two patients, grade B in four, grade C in one, and grade D in six ([Table 2](#t2-copd-13-3503){ref-type="table"}).

In the 387 ICS-untreated patients with COPD, 38 developed pneumonia. The incidence of pneumonia among the untreated patients was 9.82%. The median age was 78 years (51--91 years), and 89% were men. Nine patients had malignant tumors, seven patients had diabetes, and three had heart failure. Classification of COPD was defined by GOLD A--D grades, with grade A in 15 patients, grade B in 10, grade C in 1, and grade D in 12. In the ICS-untreated group, pneumonia occurred more frequently in grades A and D ([Table 2](#t2-copd-13-3503){ref-type="table"}). Especially in grade D, ICS-untreated patients with COPD developed pneumonia more frequently than did ICS-treated patients with COPD (*P*=0.019).

The risk of pneumonia was higher in ICS-untreated patients than in ICS-treated patients (*P*=0.037) ([Table 3](#t3-copd-13-3503){ref-type="table"}). The rate of pneumonia per observation days was also investigated. The incidence of pneumonia in ICS-treated patients was lower than that in ICS-untreated patients (*P*=0.004). This finding indicated that in the pneumonia group, a longer observation did not lead to an increase in the incidence of pneumonia. The relationship of the incidence rate of pneumonia and the observation period was investigated. In the early phase of the follow-up period, pneumonia frequently occurred in ICS-untreated patients. In the late phase, the incidence of pneumonia between ICS-treated and ICS-untreated patients appeared to be similar ([Figure 1](#f1-copd-13-3503){ref-type="fig"}).

The median period of ICS use was 972 days (29--1,677 days). Ten (77%) patients were treated with ICS for longer than 1 year, and six patients were treated for longer than 3 years. Eleven patients used FP/SM, one patient used FP, and no patients used BUD/FM or BUD. One patient used ciclesonide. In ICS-untreated patients, long-acting beta 2 agonist or long-acting muscarinic antagonist users were more frequent in the pneumonia group than in the nonpneumonia group. Moreover, in regard to the ICS regimen, pneumonia occurred in 5.70% of patients in the FP/SM group (11/193 cases) and in 0% in the BUD/FM group (0/30 cases). These findings indicated that FP/SM use tended to show a higher risk of pneumonia than did BUD/FM use (*P*=0.1961).

In the ICS-treated group, the median Age-Dehydration, Respiration, Orientation, and Pressure score, which rates the severity of pneumonia determined by the Japan Respiratory Society 2005, was 2.[@b13-copd-13-3503] The median number of hospitalized days was 14 (5--33 days). Ten patients recovered, two were transferred to other hospitals, and one died of pneumonia. Both transferred patients finally recovered. In the ICS-untreated group, the median Age-Dehydration, Respiration, Orientation, and Pressure score was 2. The median number of hospitalized days was 11 (6--41 days). Thirty-one patients recovered, three patients were transferred to other hospitals, and four patients died of pneumonia. All transferred patients finally recovered. The mortality rate in ICS-treated patients with COPD was 7.7%, while that in ICS-untreated patients was 10.5% (*P*=0.767).

We then compared the incidence of pneumonia by ICS dose. Two patients with low-dose ICS developed pneumonia. Forty-five patients with COPD used a low dose of ICS, and their incidence of pneumonia was 4.44%. The incidence of pneumonia with an intermediate dose of ICS was 3.28% (4 patients had pneumonia among 122 patients with COPD). The incidence of pneumonia with a high dose of ICS was 10% (3 patients had pneumonia among 30 patients with COPD). The incidence rate tended to be high among patients who received a high dose of ICS (10%), but this was not significant (odds ratio: 0.34, 95% CI: 0.08--1.42, *P*=0.143). These results indicated a possible relationship between ICS, especially high-dose ICS, and pneumonia. The relationship between duration of ICS treatment and pneumonia was not demonstrated.

Among ICS-treated patients, *Streptococcus pneumoniae* was observed in two, *Haemophilus influenzae* in one, *Moraxella catarrhalis* in none, and others in one patient. The bacteria of concern were unknown in nine patients. Among ICS-untreated patients, *S. pneumoniae* was observed in five, *H. influenzae* in five, *M. catarrhalis* in one, and others in six patients. The bacteria of concern were unknown in 21 patients.

To examine the risk factors of pneumonia besides ICS, we compared the clinical characteristics of 6 patients in the pneumonia group with 12 patients in the nonpneumonia group. The duration of hospitalized days, history of smoking, history of oral corticosteroid, oxygen therapy, history of pneumococcal vaccine, albumin levels, and BMI were compared between the groups. Immunosuppressive medications were not administered. Impairment of lung function was not examined. BMI was significantly lower (*P*=0.02) in the pneumonia group than in the nonpneumonia group ([Table 4](#t4-copd-13-3503){ref-type="table"}). However, there was no significance of BMI in multivariate analysis (odds ratio: 0.45, 95% CI: 0.19--1.02, *P*=0.055).

Discussion
==========

In this study, we evaluated the risk of pneumonia in ICS-treated Japanese patients with COPD. Although several reports on ICS and pneumonia have been published, to the best of our knowledge, this is the first report to examine the relationship between ICS and pneumonia in patients with COPD in Japan. We found that the incidence of pneumonia was not high in our patients, especially those receiving BUD/FM, and ICS use did not appear to affect the risk of pneumonia. Moreover, in the GOLD-D score group, ICS-untreated patients with COPD developed pneumonia more frequently than did ICS-treated patients with COPD. In the TORCH study, the ICS group had a significantly higher frequency of pneumonia than did the placebo group.[@b6-copd-13-3503] A plausible explanation for the difference in findings between our study and the TORCH study is that the dose of ICS was smaller in our study than in the TORCH study. We could not demonstrate significance concerning the dose of ICS because we included a small number of patients. However, the dose of ICS could have affected the onset of pneumonia in our study. Additionally, the type of ICS was different between studies. In this study, FP/SM use tended to show a higher risk of pneumonia than did BUD/FM use. Since 30 patients used BUD/FM in our study, a portion of BUD/FM use might affected lower incidence of pneumonia in our study. We also found that pneumonia occurred in ICS-untreated patients more frequently than ICS-treated patients in the early phase during follow-up ([Figure 1](#f1-copd-13-3503){ref-type="fig"}). The reason for this finding is unclear. However, ICS could decrease the occurrence of pneumonia in the early phase of induction, or ICS-untreated patients could have comorbidities that are susceptible to pneumonia. In the late phase, the incidence of pneumonia appeared to be similar between ICS-treated and ICS-untreated patients in our study. Another plausible explanation for the difference between studies is a difference in race. Compared with Caucasians, Japanese patients with COPD appear to be older when entering similar clinical trials, and their quality of life scores and prognosis appear better, despite similar pulmonary function impairment.[@b14-copd-13-3503] Racial differences in the risk of contracting pulmonary diseases, such as drug-induced pneumonia with gefitinib administration, have been well documented.[@b12-copd-13-3503] This possibility needs to be investigated in a future study.

Mortality due to pneumonia was not higher in patients who received ICS than in untreated patients. Kew et al[@b15-copd-13-3503] reported similar mortality results and found that ICS increased the risk of serious adverse pneumonia events but did not significantly affect mortality in treated patients compared with controls. In regard to the risk of pneumonia, ICS is not a risk factor for increasing mortality in Japanese patients with COPD.

Risk factors for pneumonia other than ICS use were also investigated in our study. Our findings suggest that BMI may be a risk factor in patients with COPD, although multivariate analysis did not show a significant difference. Progression of COPD is associated with loss of body weight.[@b16-copd-13-3503] In our study, although even patients with severe COPD were administered ICS, loss of body weight appeared to be a more influential risk factor than ICS use.

We examined the frequency of pneumonia between patients who received FP/SM and those who received BUD/FM. FP/SM use tended to increase the risk of pneumonia more than BUD/FM use, which is similar to a previous study.[@b11-copd-13-3503] None of the patients who used BUD/FM developed pneumonia in the present study. Janson et al[@b11-copd-13-3503] suggested that FP affects intracellular steroid receptors more than BUD, and FP is able to penetrate at the site of action. In this manner, the FP/SM regimen might inhibit the protection mechanism against bacterial infection.

Limitations
===========

Several limitations that are associated with the present study warrant mention. First, this study was retrospective and is thus less reliable than a prospective study. Second, our study population was relatively small. We conducted our study at a single institution, and only 60 patients had been treated with ICS in the long term (\>3 years). The number of cases of pneumonia in our study was also relatively low compared with previous reports.[@b6-copd-13-3503] To examine the risk factors of pneumonia besides ICS, impairment of lung function was not examined. However, recently, ICS was shown to decrease the mortality rate in COPD pneumonia in Japan.[@b17-copd-13-3503] We believe that ICS use is safe in Japan. We are planning to conduct a prospective study in multiple institutions.

Conclusion
==========

The present study shows that the frequency of pneumonia and mortality is not increased with ICS administration in Japan. ICS might be safely used in Japanese patients with COPD. Appropriate treatment for COPD should be investigated in each country because there are apparent differences in lung diseases among races.
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![Incidence rate of pneumonia and the observation period.\
**Notes:** The relationship of the incidence rate of pneumonia and the observation period is shown. The dashed line indicates pneumonia cases in ICS-untreated patients with COPD. The solid line indicates pneumonia cases in ICS-treated patients. In the early phase of the observation period, the rate of pneumonia was high in ICS-untreated patients. In the late phase, the incidence of pneumonia was similar between ICS-treated and ICS-untreated patients.\
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###### 

Demographic and clinical characteristics of patients with COPD

  Parameters                                   ICS group (n=252)   Non-ICS (n=387)   *P*-value
  -------------------------------------------- ------------------- ----------------- -----------
                                                                                     
  Median (range) age (years)                   75 (47--94)         73 (31--95)       0.074
  Gender (male/female)                         211/41              337/50            0.248
  Median (range) number of days of follow-up   160 (12--1,688)     118 (1--1,684)    0.631
  Duration of ICS treatment (days)                                                   
   0--365                                      142                                   
   366--730                                    27                                    
   731--1,095                                  20                                    
   Over 1,096                                  60                                    
  Type of ICS, n (%)                                                                 
   FP/SM                                       193 (76.6)                            
   BUD/FM                                      30 (11.9)                             
   FP                                          12 (4.8)                              
   BUD                                         2 (0.8)                               
   Others                                      15 (6.0)                              
  Doses of ICS treatment                                                             
   Low dose                                    45                                    
   Intermediate                                122                                   
   High                                        30                                    
   Others (changed doses)                      55                                    
  Combination of bronchodilators, n                                                  
   LABA                                        228                 188               \<0.001
   LAMA                                        149                 170               \<0.001
  Comorbidities, n                                                                   
   Malignant tumor                             72                  104               0.651
   Diabetes mellitus                           23                  51                0.130
   Ischemic heart disease                      11                  18                1.000
   Heart failure                               10                  27                0.122
  GOLD score                                                                         
   A                                           32                  217               \<0.001
   B                                           90                  88                0.233
   C                                           14                  18                0.711
   D                                           113                 64                \<0.001

**Note:** *P*-values in bold \<0.05 were regarded as statistically significant.

**Abbreviations:** BUD, budesonide; BUD/FM, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; FP, fluticasone; FP/SM, fluticasone/salmeterol; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting beta 2 agonist; LAMA, long-acting muscarinic antagonist.

###### 

Demographic and clinical characteristics of pneumonia in patients with COPD

  Parameters                                   Pneumonia group in ICS (n=13)   Nonpneumonia in ICS (n=239)   *P*-value   Pneumonia group in ICS untreated (n=38)   Nonpneumonia in ICS untreated (n=349)   *P*-value
  -------------------------------------------- ------------------------------- ----------------------------- ----------- ----------------------------------------- --------------------------------------- -----------
                                                                                                                                                                                                           
  Median (range) age (years)                   80 (69--94)                     75 (47--94)                   0.052       78 (51--91)                               72 (31--95)                             0.009
  Gender (male/female)                         12/1                            199/40                        0.700       34/4                                      303/46                                  0.802
  Median (range) number of days of follow-up   972 (29--1,677)                 139 (12--1,688)               **0.010**   441 (1--1,680)                            100 (1--1,684)                          **0.025**
  Duration of ICS treatment (days)                                                                                                                                                                         
  0--365                                       3                               139                           0.250                                                                                         
  366--730                                     2                               25                            0.637                                                                                         
  731--1,095                                   2                               18                            0.276                                                                                         
  Over 1,096                                   6                               54                            0.087                                                                                         
  Type of ICS, n (%)                                                                                                                                                                                       
  FP/SM                                        11 (84.6)                       182 (76.2)                    0.738                                                                                         
  BUD/FM                                       0 (0)                           30 (12.6)                     0.375                                                                                         
  FP                                           1 (7.7)                         11 (4.6)                      0.478                                                                                         
  BUD                                          0 (0)                           2 (0.8)                       1.000                                                                                         
  Others                                       1 (7.7)                         14 (5.9)                      0.559                                                                                         
  Combination of bronchodilators, n (%)                                                                                                                                                                    
  LABA                                         11 (84.6)                       217 (90.8)                    1.000       28 (73.6)                                 160 (45.8)                              **0.001**
  LAMA                                         8 (61.5)                        141 (59.0)                    1.000       25 (65.7)                                 145 (41.5)                              **0.006**
  Comorbidities, n                                                                                                                                                                                         
  Malignant tumor                              6                               66                            0.204       9                                         95                                      0.705
  Diabetes mellitus                            2                               21                            0.337       7                                         44                                      0.314
  Ischemic heart disease                       0                               11                            1.000       1                                         17                                      1.000
  Heart failure                                2                               8                             0.088       3                                         24                                      0.739
  GOLD score                                                                                                                                                                                               
  A                                            2                               30                            0.673       15                                        202                                     **0.038**
  B                                            4                               86                            0.776       10                                        78                                      0.547
  C                                            1                               13                            0.533       1                                         17                                      1.000
  D                                            6                               107                           1.000       12                                        52                                      **0.019**

**Note:** *P*-values in bold \<0.05 were regarded as statistically significant.

**Abbreviations:** BUD, budesonide; BUD/FM, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; FP, fluticasone; FP/SM, fluticasone/salmeterol; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting beta 2 agonist; LAMA, long-acting muscarinic antagonist.

###### 

Incidence of pneumonia in patients with COPD with or without ICS number of pneumonia cases and observation days in this study

  Parameters                  ICS-treated group   ICS-untreated group   *P*-value
  --------------------------- ------------------- --------------------- -----------
  Pneumonia                                                             
   Number of cases            13                  38                    0.037
   Total observation (days)   12,324              11,249                0.004
  Without pneumonia                                                     
   Number of cases            239                 349                   
   Total observation (days)   120,679             115,461               

**Abbreviations:** COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid.

###### 

Non-ICSrisk factors for pneumonia

  Parameters                           Pneumonia (n=6)   Nonpneumonia (n=12)   *P*-value   Multivariate analysis, *P*-value
  ------------------------------------ ----------------- --------------------- ----------- ----------------------------------
                                                                                           
  Duration of hospitalization (days)   1,022.2           945.7                 0.72        
  History of smoking                   6                 12                    1           
  Using oral corticosteroids           5                 10                    1           
  Oxygen therapy                       2                 3                     0.71        
  Pneumococcal vaccine                 3                 2                     0.14        
  Albumin (g/dL)                       3.8               3.86                  0.76        
  BMI                                  18.3              21.9                  0.02        0.055

**Abbreviations:** BMI, body mass index; ICS, inhaled corticosteroid.
